Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

>2 years Efficacy phase (II)Confirmation phase (III)No Placebo Standard Medicines Oral InjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Venclyxto

Venclyxto is a medicine used to treat certain types of blood cancer, including some forms of leukemia and lymphoma.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Glofitamab

Glofitamab is a lab-made antibody that helps the immune system target and kill abnormal B cells in certain types of B-cell lymphoma.

Obinutuzumab

Obinutuzumab is a lab-made antibody that targets and helps eliminate B cells to treat certain blood cancers like chronic lymphocytic and follicular lymphoma.

Venetoclax

Venetoclax is a substance used to treat certain blood cancers by helping cancer cells die.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Institut Jules Bordet

Hematology

Negenmanneke, Belgium

Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur

Hematology

Profondeville, Belgium

Az St-Jan Brugge-Oostende A.V.

Hematology

Sint-Andries, Belgium

Sponsor: Lymphoma Academic Research Organisation

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.